A detailed history of Russell Investments Group, Ltd. transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 22,295 shares of ZNTL stock, worth $88,065. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,295
Holding current value
$88,065
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.9 - $4.57 $64,655 - $101,888
22,295 New
22,295 $81,000
Q3 2023

Nov 13, 2023

SELL
$19.63 - $28.29 $126,829 - $182,781
-6,461 Reduced 6.1%
99,412 $1.99 Million
Q2 2023

Aug 10, 2023

BUY
$17.41 - $30.05 $884,480 - $1.53 Million
50,803 Added 92.25%
105,873 $2.99 Million
Q1 2023

May 09, 2023

SELL
$16.14 - $24.94 $295,055 - $455,928
-18,281 Reduced 24.92%
55,070 $947,000
Q4 2022

Feb 08, 2023

SELL
$18.07 - $25.6 $115,919 - $164,224
-6,415 Reduced 8.04%
73,351 $1.48 Million
Q3 2022

Nov 04, 2022

BUY
$20.23 - $31.73 $40,014 - $62,761
1,978 Added 2.54%
79,766 $1.73 Million
Q2 2022

Jul 29, 2022

BUY
$17.91 - $52.25 $343,316 - $1 Million
19,169 Added 32.7%
77,788 $2.18 Million
Q1 2022

May 05, 2022

SELL
$41.58 - $80.89 $26,819 - $52,174
-645 Reduced 1.09%
58,619 $2.7 Million
Q4 2021

Jan 21, 2022

BUY
$66.92 - $84.79 $117,176 - $148,467
1,751 Added 3.04%
59,264 $4.98 Million
Q3 2021

Nov 08, 2021

BUY
$46.83 - $73.5 $514,661 - $807,765
10,990 Added 23.62%
57,513 $3.83 Million
Q2 2021

Aug 04, 2021

BUY
$37.41 - $62.25 $867,425 - $1.44 Million
23,187 Added 99.36%
46,523 $2.47 Million
Q4 2020

Feb 08, 2021

BUY
$31.71 - $57.97 $739,984 - $1.35 Million
23,336 New
23,336 $1.21 Million

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $225M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.